Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants

Reference

• Johns_Hopkins_University. COVID-19 dashboard by the center for systems science and engineering (CSSE) at Johns Hopkins University (JHU). 2020. http://publichealthupdate.com/jhu/.
   Google Scholar
• Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021;184(9):2348-2361.e6.
   PubMed Web of Science ®Google Scholar
• Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020;9:e61312.
   PubMed Web of Science ®Google Scholar
• Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409-424.
   PubMed Web of Science ®Google Scholar
• Plante JA, Mitchell BM, Plante KS, et al. The variant gambit: COVID-19’s next move. Cell Host Microbe. 2021;29(4):508-515.
   PubMed Web of Science ®Google Scholar
• BioValley. Overview of global SARS-COV-2 vaccine development. 2021. https://mp.weixin.qq.com/s/TCg6-PLBMS74eQ6rAsoszg.
   Google Scholar
• Rogers TF, Zhao F, Huang D, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369(6506):956-963.
   PubMed Web of Science ®Google Scholar
• Mendoza P, Lorenzi JCC, Gaebler C. COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research. Curr Opin HIV AIDS. 2021;16(1):25-35.
   PubMed Web of Science ®Google Scholar
• Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020;5(12):1598-1607.
   PubMed Web of Science ®Google Scholar
• Pradenas E, Trinité B, Urrea V, et al. Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes. Med (N Y). 2021;2(3):313-320.e4.
   PubMedGoogle Scholar
• Liao Y, Zhang Y, Zhao H, et al. Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine. Emerg Microbes Infect. 2021;10(1):1112-1115.
   PubMed Web of Science ®Google Scholar
• Wang GL, Wang ZY, Duan LJ, et al. Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization. N Engl J Med. 2021;384(24):2354-2356.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021;384(20):1885-1898.
   PubMed Web of Science ®Google Scholar
• Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130-135.
   PubMed Web of Science ®Google Scholar
• Garcia-Beltran WF, Lam EC, St Denis K, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184(9):2372-2383.e9.
   PubMed Web of Science ®Google Scholar
• Cantón R, De Lucas Ramos P, García-Botella A, et al. New variants of SARS-CoV-2. Rev Esp Quimioter. 2021;34(5):419-428.
   PubMed Web of Science ®Google Scholar
• Quinonez E, Vahed M, Hashemi Shahraki A, et al. Structural Analysis of the Novel Variants of SARS-CoV-2 and Forecasting in North America. Viruses. 2021;13(5):930.
   PubMed Web of Science ®Google Scholar
• Che Y, Liu X, Pu Y, et al. Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults. Clin Infect Dis. 2021;73(11):e3949-e3955.
   PubMed Web of Science ®Google Scholar
• Pu J, Yu Q, Yin Z, et al. The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18–59 years: A phase I randomized, double-blinded, controlled trial. Vaccine. 2021;39(20):2746-2754.
   PubMed Web of Science ®Google Scholar
• Li R. Transient transfection of CHO cells using linear polyethylenimine is a simple and effective means of producing rainbow trout recombinant IFN-γ protein. Cytotechnology. 2015;67(6):987-993.
   PubMed Web of Science ®Google Scholar
• Zhang X, Jiang Q, Xu X, et al. Immune mechanisms induced by an HSV-1 mutant strain: Discrepancy analysis of the immune system gene profile in comparison with a wild-type strain. Vaccine. 2018;36(18):2394-2402.
   PubMed Web of Science ®Google Scholar
• Ostrov DA. Structural Consequences of Variation in SARS-CoV-2 B.1.1.7. J Cell Immunol. 2021;3(2):103-108.
   PubMedGoogle Scholar
• Wang R, Chen J, Gao K, et al. Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries. Genomics. 2021 Jul;113(4):2158-2170.
   PubMed Web of Science ®Google Scholar
• Frazier L, Lubinski B, Tang T, et al. Spike protein cleavage-activation mediated by the SARS-CoV-2 P681R mutation: a case-study from its first appearance in variant of interest (VOI) A.23.1 identified in Uganda. bioRxiv. 2021 Nov 11;2021.06.30.450632. doi: 10.1101/2021.06.30.450632.
   Google Scholar
• Schnyder JL, Garcia Garrido HM, De Pijper CA, et al. Comparison of equivalent fractional vaccine doses delivered by intradermal and intramuscular or subcutaneous routes: A systematic review. Travel Med Infect Dis. 2021;41:102007.
   PubMed Web of Science ®Google Scholar
• Criscuolo E, Caputo V, Diotti RA, et al. Alternative Methods of Vaccine Delivery: An Overview of Edible and Intradermal Vaccines. J Immunol Res. 2019;2019:8303648.
   PubMed Web of Science ®Google Scholar
• Hunsaker BD, Perino LJ. Efficacy of intradermal vaccination. Vet Immunol Immunopathol. 2001;79(1-2):1-13.
   PubMed Web of Science ®Google Scholar
• Fan S, Liao Y, Jiang G, et al. Study of integrated protective immunity induced in rhesus macaques by the intradermal administration of a bivalent EV71-CA16 inactivated vaccine. Vaccine. 2020;38(8):2034-2044.
   PubMed Web of Science ®Google Scholar
• Chen H, Xie Z, Long R, et al. Immunological evaluation of an inactivated SARS-CoV-2 vaccine in rhesus macaques. Mol Ther Methods Clin Dev. 2021;23:108-118.
   Google Scholar
• CNBC. China has administered more than 1 billion doses of its Covid-19 vaccines. 2021. https://www.cnbc.com/2021/06/21/china-covid-19-vaccines-more-than-1-billion-doses-administered.html.
   Google Scholar
• Chen Y, Zhu L, Huang W, et al. Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination. Emerg Microbes Infect. 2021;10(1):1390-1403.
   PubMed Web of Science ®Google Scholar
• Vaine M, Wang S, Hackett A, et al. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine. 2010;28(17):2999-3007.
   PubMed Web of Science ®Google Scholar
• Excler JL, Kim JH. Novel prime-boost vaccine strategies against HIV-1. Expert Rev Vaccines. 2019;18(8):765-779.
   PubMed Web of Science ®Google Scholar
• He Q, Mao Q, An C, et al. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg Microbes Infect. 2021;10(1):629-637.
   PubMed Web of Science ®Google Scholar
• Zhang J, He Q, An C, et al. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine. Emerg Microbes Infect. 2021;10(1):1598-1608.
   PubMed Web of Science ®Google Scholar
• Li Y, Bi Y, Xiao H, et al. A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques. Emerg Microbes Infect. 2021;10(1):342-355.
   PubMed Web of Science ®Google Scholar
• Nelson KS, Janssen JM, Troy SB, et al. Intradermal fractional dose inactivated polio vaccine: a review of the literature. Vaccine. 2012;30(2):121-125.
   PubMed Web of Science ®Google Scholar